33 results about "Nystatin" patented technology

The invention relates to the technical field of bioengineering, in particular to streptomyces noursei capable of producing multimycotin B and application of the streptomyces noursei. According to the invention, gene editing is carried out on the nysL gene and the nysGtf gene or a combination thereof in the streptomyces nosella, so that the yield of the polymycotin B in the streptomyces nosella is remarkably improved. According to the streptomyces noursei for producing the multi-fungal element B, the multi-fungal element B can be efficiently synthesized and accumulated by utilizing low-cost raw materials, the yield of the multi-fungal element B is remarkably increased, and the streptomyces noursei can be used for producing the multi-fungal element B or increasing the content ratio of the multi-fungal element B in prepared nystatin. According to the streptomyces noursei and the method for producing the multi-fungal element B by using the streptomyces noursei, provided by the invention, a strain resource and an effective method are provided for producing the multi-fungal element B and producing nysfungin with a high multi-fungal element B content ratio, and the streptomyces noursei has a relatively good application prospect.

A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.

The invention provides a compound nystatin ointment and a preparation method thereof, and relates to the technical field of medicine preparation, the compound nystatin ointment comprises active ingredients of nystatin, neomycin sulfate, triamcinolone acetonide and permethrin, and the formula comprises liquid paraffin, white vaseline, wool fat, hexadecanol, PEG-30 dipolyhydroxystearate and glyceryl monoisostearate. According to the compound nystatin ointment preparation prescription process disclosed by the invention, the phenomenon of ointment matrix layering in the use process of commercially available products is mainly solved. According to a pharmaceutical research test, the stability of the compound nystatin ointment is superior to that of a commercially available original development agent, the ointment body character and the stability of active ingredients can be kept under the conditions of high temperature, high humidity, low temperature, freeze thawing and illumination, the maximum single impurity content and the total impurity content in the product are not obviously increased, and the quality is controllable. And meanwhile, an in-vitro transdermal test (IVPT) accidentally finds that the retention amount of related active ingredients is higher than that of the original development agent, and the drug effect is obviously improved. Through clinical test research, the compound nystatin ointment disclosed by the invention can be used for effectively treating external otitis caused by bacteria sensitive to neomycin, fungi sensitive to nystatin and ear mites sensitive to permethrin of dogs and cats.

The present application relates to a method for accumulating glutathione, wherein activated yeast is fermented in a fermentation medium, nystatin and sodium dodecyl sulfate (SDS) are added in the logarithmic or stationary phase of the yeast growth, and the fermentation is continued to obtain the glutathione. The present application can significantly increase the production of glutathione, improve the utilization of raw materials, and reduce the production cost.

The invention relates to the technical field of gene engineering, in particular to an application of a YJL151C gene or a protein thereof. On the basis of SCRaMbLE rearrangement, bioinformatics analysis and phenotypic analysis are combined for gene mining work, and a series of tolerance-related genes are obtained. The research finally finds that the over-expression of the YJL151C gene can improve the drug resistance of the strain to nystatin, and a drug-resistant strain with precise corrosion resistance is provided for the food fermentation industry. The strain can also be cooperated with other antagonistic microorganisms to be used for biological prevention and control of crops or feed.

The invention discloses a compound nysfungin ointment, which comprises an active component, a preservative, a humectant, a thickening agent, a grease matrix and an antibacterial agent, the active component is selected from one or more of self-made mycotoxin, neomycin sulfate, permethrin and triamcinolone acetonide, the preservative is selected from benzalkonium chloride, the humectant is selected from glycerol, the thickening agent is selected from glycerol, and the grease matrix is selected from a grease matrix. The humectant is selected from humectant, the thickening agent is selected from carbomer, the grease matrix is selected from liquid paraffin and / or wool fat, the antibacterial agent is selected from thymol, and the ratio of the humectant to the thickening agent is (2-7): (0.5-3) in parts by mass. By accurately controlling the proportion of the humectant to the thickener, the texture of the ointment can be optimized, so that the skin permeability is improved, the medicine absorption is promoted, the treatment effect is improved, in addition, the form of the ointment can be kept, the active ingredients are prevented from being degraded, and the shelf life of the preparation is prolonged.

The invention relates to the technical field of biology, in particular to a nystatin and low-intensity pulsed ultrasound synergistic antifungal method and application thereof. The nystatin and ultrasonic combined antifungal method comprises the following steps: under the assistance of ultrasonic waves, applying nystatin, and carrying out antifungal treatment. The application discovers that nystatin combined with low-intensity pulsed ultrasound can significantly improve the antibacterial effect on fungi (specifically candida albicans) in vitro, has an obvious injury effect on cell structures, and can effectively and rapidly remove candida albicans colonized in vagina, improve vaginal mucosa structure and relieve inflammation symptoms in rabbit bodies, so that the anti-inflammatory effect of the rabbit bodies is improved, and the anti-inflammatory effect of the rabbit bodies is improved. The expression level of vaginal epithelial apoptotic cells is reduced, and the treatment effect on high-drug-resistance and high-recurrence-rate infectious diseases induced by fungi (specifically candida albicans) is remarkably improved.

1. Name of the design product: Packaging box (Compound Nystatin Ointment). 2. Use of the design product: The design product is used for packaging drugs. 3. Design key points of the design product: The combination of shape and pattern. 4. Picture or photograph that best shows the design key points: Front view.

The present invention belongs to the field of functional material preparation and discloses a method for preparing a nystatin adsorbent based on attapulgite. The specific preparation steps are: (1) pretreating the attapulgite; (2) coating the surface of the pretreated attapulgite with a layer of dopamine; (3) modifying the dopamine with a layer of bromine initiator; (4) preparing a surface-imprinted adsorption material with boron affinity by free radical polymerization; and (5) conducting a nystatin adsorption test on the material. The adsorption separation material obtained by this preparation method has excellent mass transfer kinetics and adsorption efficiency, is low in cost, is simple to prepare, has a specific adsorption effect on nystatin, and can be used to purify crude nystatin.

A strain of Dubois nystomatitis ( Dubosiella newyorkensis TZF-002 and its application in the fermentation and conversion of rare ginsenosides belong to the field of microbiology. The *Duboscirella nymphaeus* mentioned herein (…) Dubosiella newyorkensis TZF-002 was deposited at the China Center for Type Culture Collection on December 15, 2025, with accession number CCTCC NO: M 20252890. This invention uses total ginsenosides as raw material, first utilizing the high-β-glucosidase-producing *Duboscirella nystatin* (…). Dubosiella newyorkensis The TZF-002 method employs a mild and controlled fermentation process to transform primary ginsenosides, followed by high-temperature steam treatment, ultimately yielding rare ginsenosides Rg6, F4, Rh4, S-Rg3, R-Rg3, Rk1, and Rg5 efficiently. This method, for the first time, combines the enzymatic transformation characteristics of intestinal symbiotic bacteria with physical treatment, offering advantages such as mild conditions, low cost, and significantly superior product variety and content compared to single processes. It effectively improves the yield, bioavailability, and physiological activity of rare saponins.

The present invention relates to a pharmaceutical composition for preventing or treating flavivirus infections. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, triflurazine, dihydrostreptomycin, hydroxychloroquine, thiolidazine hydrochloride, efavirenz, mitefonew, nystatin, micafungin, bleomycin, remistat, montelukast, norfloxacin, nedaplatin and cephalosporin, and the pharmaceutical composition is prepared from the following raw materials in parts by weight. It is possible to exhibit an excellent growth inhibition or inactivation effect on different species of flavivirus.

The utility model relates to the field of soft capsule quality detectors, and discloses a nifuratel nystatin vaginal soft capsule quality detection device which comprises a machine body and a mounting frame, a transmission frame is fixedly mounted on the inner wall of the machine body, a display is fixedly connected to the surface of the machine body, two sliding grooves are formed in the inner wall of the mounting frame, and the transmission frame is fixedly connected with the display. A sliding block is slidably connected to the inner wall of the sliding groove, a motor is fixedly mounted at one end of the sliding block, a cleaning roller is fixedly connected to the output end of the motor, and the bottom end of the mounting frame is welded to the top of the conveying frame; the mounting frame is connected with the top of the conveying frame, a sliding block is slidably connected into a sliding groove in the inner wall of the mounting frame, a motor is mounted at one end of the sliding block, the output end of the motor is connected with a cleaning roller, and the bottom end of the cleaning roller is slidably connected with the top of the conveying frame, so that the cleaning roller is controlled to clean the surface of the conveying frame after the motor is started; and therefore, the conveying frame polluted by the soft capsule with the damaged shell can be cleaned.

The invention provides a preparation method of a composition containing nystatin. The preparation method comprises the following steps: preparing a base solution containing a suspending aid and buffer salt; preparing a wetting solution containing nystatin; cooling the base solution to 10-15 DEG C, and adding the wetting solution to prepare a mixed solution; carrying out heat preservation on the mixed solution at 10-15 DEG C for a first time, and then carrying out heat preservation at 45-50 DEG C for a second time; and cooling the mixed solution after the heat preservation is finished, then adding a preservative and a flavoring agent, and adjusting the pH value of the mixed system to 6.5-7.2 to prepare the composition containing nystatin. The preparation method is high in production efficiency, and the prepared composition containing nystatin is stable in quality.

The invention belongs to the technical field of medicine preparation, and particularly relates to low-irritation nystatin ointment for pets and a preparation method of the low-irritation nystatin ointment. The low-irritation nystatin ointment for pets provided by the invention is prepared from the following raw materials in percentage by mass: 0.1 to 0.5 percent of neomycin sulfate, 5 to 25 percent of sustained-release nystatin, 0.05 to 0.2 percent of triamcinolone acetonide, 0.1 to 2.5 percent of permethrin nanoparticles and the balance of paraffin. According to the low-irritation nystatin ointment for pets provided by the invention, the nystatin ointment with good bactericidal activity, stable components and low irritation is obtained by modifying and optimizing the raw material components in the nystatin ointment, and the nystatin ointment is beneficial to treating fungal infection diseases of pets.

A strain of *Duboscirella nystatin* that produces β-glucosidase ( Dubosiella newyorkensis TZF-001 and its application in the fermentation and conversion of ginsenosides belong to the field of probiotic fermentation. This *Duboscirella nystatin* (TZF-001) and its application in the fermentation and conversion of ginsenosides belong to the field of probiotic fermentation. Dubosiella newyorkensis TZF-001 was deposited at the China Center for Type Culture Collection on December 15, 2025, with accession number CCTCC NO: M20252889. This invention uses ginsenoside Rb1 as a raw material and utilizes *Duboscirella nystatin*, a bacterium that produces high levels of β-glucosidase. Dubosiella newyorkensis The TZF-001 fermentation method converts ginsenosides (Rb1) to ginsenoside Rd. After fermentation, ginsenoside Rb1 can be completely converted to Rd. This invention avoids the dependence on acid-base hydrolysis, high temperature and pressure, and steam treatment in traditional methods. Its reaction conditions are mild, and it boasts advantages such as environmental friendliness, low cost, and high product purity. This opens up a new technological path for the green and low-cost preparation of ginsenoside Rd, and has significant innovative and promotional value in the industrialization of natural drug active ingredients.

The application relates to the field of biological medicine, and discloses an iridium complex for dynamic detection of mitochondrial viscosity and tumor differentiation, a preparation method and application thereof, and a structure formula of the iridium complex is as follows: The iridium complex Ir-visc in the application is based on a double-locking targeting strategy of electrostatic adsorption and probe-protein docking, does not depend on MMP, and stably anchors mitochondria in cells; the iridium complex exhibits excellent high-viscosity-activated one-photon (OP) and two-photon (TP) phosphorescence characteristics, is not disturbed by other factors in a living body, can be used for monitoring viscosity changes in a complex biological system; can be used as a mitochondrial phosphorescence probe to differentiate tumor cells and normal cells, and monitor changes of mitochondrial viscosity of cells under the stimulation of starvation and an antifungal drug nystatin; and not only has strong tumor tissue recognition capability, but also has deep tissue penetration and in-vivo imaging capability.

This invention discloses a nystatin microsphere with targeted enhanced antifungal function, its preparation method, and its application. The microsphere uses sodium alginate as a carrier, internally encapsulating the antifungal drug nystatin. The surface is covalently modified with the β-glucan binding domain of the Dectin-1 protein, constructing a smart drug delivery system with fungal targeting function. The microsphere preparation process is simple and reproducible, and can be scalable using an emulsion-ionic crosslinking method combined with protein coupling technology. In vitro characterization shows that the microspheres have uniform particle size and stable dispersion, and Dectin-1 modification significantly enhances their specific binding ability against Candida albicans. This targeted delivery system, while successfully preserving drug activity, significantly improves the antifungal efficiency of nystatin through Dectin-1-mediated targeting, achieving efficacy close to that of free drug, and providing a new strategy for constructing highly efficient and long-acting antifungal agents.

The walnuts are rich in protein. Wild pecans in Changbai Mountains in northeast China are rich in yield, and residues after oil pressing are mostly used as feed. Active substances such as subtilin, polymyxin, nystatin and brevibacterium peptide are generated in the growth process of bacillus subtilis thalli, enzymes such as alpha-amylase, protease, lipase and cellulase are synthesized by the bacillus subtilis thalli, and the northeast walnut oil extraction residues rich in protein can be degraded. Therefore, the invention provides the method for preparing the bacillus subtilis degradation liquid from the northeast walnut oil extraction residues. The method is beneficial to comprehensive utilization of the northeast walnut oil extraction residues.

The invention discloses an application of nystatin in prevention and treatment of trichoderma koningiopsis infection with unknown scirpus juncoides, according to the method, the unknown scirpus juncoides infected with the trichoderma koningiopsis is treated by a medicine drop method by using a nystatin solution, and the death rate of the unknown scirpus juncoides infected with the trichoderma koningiopsis can be remarkably reduced; the survival rate of indoor culture of the unknown nolassa dyestua is improved, the economic benefit and the indoor rejuvenation effect of the firefly culture industry can be increased, and the method has a good application prospect.

The invention discloses a water-soluble near-infrared fluorescent probe for detecting viscosity of a biological system as well as a preparation method and application of the water-soluble near-infrared fluorescent probe. The fluorescent probe is prepared by condensing 8-hydroxyjulolidine and 4-methyl-1-(triethylene glycol monomethyl ether) quinolinium salt, the structural formula is shown in the specification, and the probe has a remarkable Stokes shift characteristic and also has the characteristics of high response speed, high selectivity, excellent biocompatibility and the like. The probe can be used for effectively monitoring viscosity changes of stress-induced onion endoepidermis cells and mung bean slice cells and dynamic changes of nystatin-induced viscosity in juvenile zebrafish bodies, and can be applied to imaging analysis of whole mung bean plants and peanut plants. Besides, the obtained fluorescent probe is simple to prepare, high in yield, mature in synthetic route, low in cost and suitable for amplified synthesis and actual production application, and a reliable tool is provided for actual application in the fields of biomedicine, agricultural monitoring and the like.

The present invention belongs to the field of pharmaceuticals, and particularly relates to an oral gel and its application. The oral gel of the present invention comprises nystatin or nistatin as the active ingredient (API), hydroxyethyl cellulose and sodium carboxymethyl cellulose, and optionally strawberry essence. The oral gel is used for treating oral candidiasis, can effectively mask the earthy smell of the API, and has strong adhesiveness, good spreadability, good palatability and high stability.

The present invention relates to a fast film-forming nystatin oral gel spray and a preparation method thereof, belonging to the field of biomedical technology, and solves the problem that the nystatin dosage form in the prior art is not suitable for children, especially newborns and infants. The fast film-forming nystatin oral gel spray includes nystatin, xanthan gum, polyethylene glycol-polyvinyl alcohol graft copolymer, glycerol and a solvent, and the solvent is water. The fast film-forming nystatin oral gel spray of the present invention is more suitable for use by children, especially newborns and infants.

The application discloses a preparation method of a nystatin fatty acid ester vaginal suppository responding to inflammation, a product and application thereof, and belongs to the field of medicine. The preparation method comprises the following steps: dissolving fatty acid in a solvent, adding a catalyst, uniformly mixing, and activating a carboxyl group of the fatty acid, adding nystatin, and stirring to obtain nystatin fatty acid ester. The fatty acid is saturated or unsaturated fatty acid with a carbon chain length of 4-17 carbons. The application effectively solves the problems that nystatin is unevenly distributed in the suppository matrix and is prone to suppository sedimentation and stratification. Meanwhile, the nystatin fatty acid ester disclosed by the application can be hydrolyzed under the action of leukocyte esterase at an inflammation site of a vagina, release nystatin raw medicine, and play a bactericidal role responding to inflammation. In the non-inflammation area, the nystatin fatty acid ester is hardly hydrolyzed into nystatin, and thus the local adverse reaction of the vagina caused by nystatin can be effectively reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to application of nystatin in preparation of a product for treating LINC00516 high-expression lung adenocarcinoma. The invention discloses the effect of the long-chain non-coding RNA LINC00516 in abnormal activation of the lung adenocarcinoma cell cycle for the first time. Researches show that LINC00516 is directly combined with CDK1, the kinase activity of CDK1 is remarkably enhanced, and the inhibitory phosphorylation level of CDK1 is reduced, so that lung adenocarcinoma cells are driven to quickly enter a G2 / M phase, and tumor cell proliferation is accelerated. The invention further innovatively proposes that nystatin is used as an intervention means, and by blocking the combination of LINC00516 and CDK1, the activity of CDK1 is reduced, and the proliferation capacity of tumor cells is inhibited. In-vivo and in-vitro experiments prove that nystatin significantly inhibits the growth of lung adenocarcinoma cells highly expressing LINC00516, so that a brand-new molecular targeted therapy strategy is provided for clinic.

The invention discloses nysfungin in-situ gel forming oil for treating fungal oral mucositis and a preparation method, and belongs to the technical field of fungal oral mucositis dressings. The nysfungin in-situ gelatinizing oiling agent comprises a drug active ingredient encapsulated in a drug carrier; the medicine active component is nysfungin, and the medicine carrier is lyotropic liquid crystal; wherein the lyotropic liquid crystal is a liquid crystal formed by lecithin (PC) and glyceryl dioleate (GDO) in ethanol and propylene glycol. The nysfungin in-situ gelatinizing oiling agent has the characteristics of long-acting antifungal effect and long-term stability, namely has the advantages of being sprayable, strong in adhesive force, long in residence time and validity period and the like.

The invention provides a method for improving vibrio splendidus infection resistance of stichopus japonicus, which is a method for preventing and treating stichopus japonicus diseases caused by vibrio splendidus by inhibiting pathogenesis related to vibrio splendidus outer membrane vesicles. The composition capable of improving the vibrio splendidus infection resistance of the stichopus japonicus comprises chlorpromazine and nystatin. The composition provided by the invention has no obvious toxicity to coelomic cells of the stichopus japonicus, and can inhibit endocytosis of OMVs to the maximum extent, so that the optimal prevention and control effect is realized. After the OMVs are treated by chlorpromazine and nystatin, the endocytosis efficiency of the OMVs is reduced by more than 50%.

The invention belongs to the technical field of organic synthesis, and provides a mitochondrial targeting and viscosity-sensitive near-infrared fluorescent probe as well as a preparation method and application thereof. The fluorescent probe has positive charges, can be selectively enriched in mitochondria, and can dynamically monitor the viscosity of the mitochondria. The synthesis steps of the probe are short, and post-treatment is easy; the selectivity, the sensitivity and the stability are high. The excitation wavelength and the emission wavelength are in a near-infrared region, so that biological autofluorescence interference can be effectively avoided, and deep tissue penetration potential is achieved. The probe has been successfully applied to real-time monitoring of mitochondrial viscosity level in cancer cell autophagy and apoptosis processes and detection of viscosity change in zebrafish under nystatin stimulation. The invention provides an efficient tool for dynamic monitoring of mitochondrial viscosity, has important application value in the aspects of early diagnosis, efficacy evaluation and the like of mitochondrial related diseases such as cancer and the like, and meets clinical and scientific research requirements.

The invention discloses a nystatin solution as well as a preparation method and application thereof, and the nystatin solution is prepared from the following raw materials in parts by weight: 20-50 parts of nystatin, 110-220 parts of dimethyl sulfoxide, 1.5-2.0 parts of a preservative, 0.5-1 part of an antioxidant and 737-880 parts of 1, 2-propylene glycol. According to the invention, a composite solvent system of dimethyl sulfoxide and propylene glycol is creatively adopted, and a remarkable synergistic effect is generated by utilizing the extremely strong dissolving capacity of dimethyl sulfoxide and the auxiliary solubilizing and diluting effects of propylene glycol. The system can completely dissolve 50 parts by weight of nystatin to form a clear, transparent and uniform stable solution, so that the technical bottleneck that nystatin cannot be prepared into a high-content solution due to insolubility in water is fundamentally solved, and a foundation is laid for drinking water administration of poultry groups.

The present invention relates to a pharmaceutical composition for preventing or treating flavivirus infections. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, triflurazine, dihydrostreptomycin, hydroxychloroquine, thiolidazine hydrochloride, efavirenz, mitefonew, nystatin, micafungin, bleomycin, remistat, montelukast, norfloxacin, nedaplatin and cephalosporin, and the pharmaceutical composition is prepared from the following raw materials in parts by weight. It is possible to exhibit an excellent growth inhibition or inactivation effect on different species of flavivirus.

The invention discloses a streptomyces strain and an application of the streptomyces strain in production of nystatin A1. The streptomyces disclosed by the invention is streptomyces albus J1074-nystatin BGC-SSC133, and the preservation number of the streptomyces albus is CGMCC (China General Microbiological Culture Collection Center) No.36300 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the streptomyces albus J1074-nystatin BGC-SSC133 can be used for efficiently preparing the nystatin A1, and the content of the nystatin A1 reaches 106.30 [mu] g / mL + / -8.45 [mu] g / mL. The method has important economic value and application prospect.